USANA Health Sciences, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2017, with comparative results for the quarter and nine months ended October 1, 2016. The request metadata says “2016 Q3,” but the filing itself is for 2017 Q3.
Business context
USANA develops and manufactures nutrition and personal-care products sold internationally through independent direct-selling Associates. It reported approximately 563,000 active Customers at September 30, 2017. Asia Pacific generated 76.1% of quarterly sales; Greater China alone generated 50.1%.
Financial performance and liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Net sales | $261.8 million | $254.2 million | $774.2 million | $753.2 million |
| Gross profit | $214.6 million | $209.2 million | $640.5 million | $619.3 million |
| Gross margin | 82.0% | 82.3% | 82.7% | 82.2% |
| Operating earnings | $31.4 million | $35.8 million | $96.6 million | $106.8 million |
| Net earnings | $23.8 million | $30.1 million | $68.4 million | $78.2 million |
| Diluted EPS | $0.97 | $1.20 | $2.75 | $3.12 |
- Quarterly sales rose 3.0% year over year; constant-currency growth was also 3.0%. Nine-month sales rose 2.8%, or 4.6% excluding currency effects.
- Quarterly operating and net margins were approximately 12.0% and 9.1%, respectively, versus 14.1% and 11.8% in the prior-year quarter. Nine-month operating and net margins were approximately 12.5% and 8.8%, versus 14.2% and 10.4%.
- Operating cash flow for the first nine months was $68.7 million, down from $81.7 million. Capital expenditures were $9.2 million, compared with $26.0 million. Cash increased to $191.7 million from $175.8 million at year-end 2016.
- Working capital was $165.0 million, up from $139.4 million at year-end. No borrowings were outstanding under the $75 million credit facility; guarantees reduced available capacity by $4.7 million. Management said cash, operating cash flow, and available credit should cover ordinary-course needs for the foreseeable future.
- USANA repurchased 865,000 shares for $50.0 million in the first nine months, averaging $57.78 per share. The remaining authorized repurchase amount was $50.0 million.
Changes, outlook, and notable items
- Quarterly sales growth was led by Greater China (+5.5%) and North Asia (+35.9%); Southeast Asia Pacific declined 3.8%, and Americas and Europe declined 2.1%. Nine-month Americas and Europe sales fell 6.1%.
- Quarterly net earnings fell 21.0%, primarily due to higher SG&A and a higher effective tax rate. SG&A increased $6.7 million in the quarter and $16.7 million year to date, reflecting convention costs, China and investigation-related costs, IT investments, and a supplier-note impairment.
- Quarterly effective tax rate was 25.8%, versus 16.6%; the nine-month rate was 30.4%, versus 26.8%. Management attributed the increases primarily to lower excess tax benefits from equity award exercises.
- Gross margin declined 30 basis points in Q3, with sales mix, higher China material costs, and scrap costs partly offset by currency and pricing. Nine-month gross margin increased 50 basis points.
- A $1.6 million impairment was recorded against a secured note receivable from a former nutrition-bar supplier after USANA stopped using the supplier. The company said it will continue assessing recoverability.
- USANA was conducting a voluntary internal investigation into BabyCare operations in China and had contacted the SEC and Department of Justice. The company said it could not predict the investigation’s duration, scope, or outcome; governmental proceedings and penalties are possible. A shareholder class action alleging securities-law violations was pending, and the company intended to defend it. A separate derivative suit was dismissed by the Utah Supreme Court in October 2017.
- Disclosure controls were deemed ineffective due to a previously reported material weakness in internal control related to the China matter. Remediation was ongoing, with management expecting completion during 2017, subject to testing. No quantified earnings or revenue guidance was provided.
- Management plans to launch the Celavive skincare line in select markets beginning January 2018 and expand into Romania, Germany, Italy, and Spain beginning mid-2018. Adoption of the new revenue-recognition standard was planned for Q1 2018; management expected no material financial-statement impact but was evaluating order-delivery timing.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied metadata says 2016 Q3, while the filing reports Q3 2017.
- Track the China internal investigation, any SEC or DOJ action, related legal costs, and remediation of the material weakness.
- Assess whether Greater China growth can offset declines in Americas and Europe and whether active-Customer trends support sales.
- Monitor the former supplier note’s collateral value and potential further impairment, as well as supplier continuity for nutrition bars.
- Review the drivers of higher SG&A and tax expense, cash conversion, and continued share repurchases against operating needs.